Sign In
Buy OKYO
$1.70
-0.0100 (-0.585%)
At Close: Jun 02, 2026
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
08:02am, Saturday, 23'rd May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate t
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
04:00am, Saturday, 23'rd May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances...
What Makes OKYO Pharma (OKYO) a New Buy Stock
01:01pm, Wednesday, 20'th May 2026
OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FTSE 100 Live: Stocks lose early gains as UK jobs market cools, IG and Currys surge
12:05pm, Tuesday, 19'th May 2026
FTSE 100 up 11 points at 10,335 UK jobs data weakens, unemployment back to 5% IG Group, Diploma, Currys, Dr Martens, SSP, Cranswick among reporters ...
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
10:00am, Tuesday, 19'th May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuro
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
07:00am, Tuesday, 19'th May 2026
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO's introduction to the broader ophthalmology community at ASCRS
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
05:58am, Tuesday, 19'th May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company...
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
07:00am, Wednesday, 29'th Apr 2026
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma to present at Eyecelerator, share urcosimod data at ARVO annual meeting
04:45am, Wednesday, 29'th Apr 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said its CEO Robert Dempsey will present at Eyecelerator on May 1 in Denver, while company leadership will also participate in...
Gold mining pullback presents a compelling buying opportunity - broker
10:51am, Tuesday, 07'th Apr 2026
The sharp pullback in gold mining stocks has created a compelling buying opportunity, that's according to JP Morgan, with the broker arguing the sector’s...
OKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentation
08:42am, Tuesday, 07'th Apr 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, has announced plans to convene a Scien
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
07:00am, Tuesday, 07'th Apr 2026
LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma Announces Chairman and Founder Acquires Shares
12:00pm, Thursday, 19'th Mar 2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma Announces Director Acquires Shares
10:00am, Thursday, 19'th Mar 2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma executive chairman increases stake with share purchase
08:12am, Thursday, 19'th Mar 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said Panetta Partners, linked to its executive chairman Gabriele Cerrone, has purchased about 10,000 shares at $1.59 each,...
